Immunoprecise Antibodies Ltd

ImmunoPrecise Antibodies Ltd. is a therapeutic antibody discovery company, which engages in the provision of human therapeutic antibody discovery and development services. The firm offers a selection of antibodies, enzymes, enzymes activity assays, arthritis animal products, proteins, deiminated proteins, and hybridoma licensing for research purposes. Its services include B cell sorting, screening and sequencing; custom, immune and naive phage display production and screening; bi-specific, tri-specific, VHH, and VNAR antibody manufacturing; antibody engineering; and antibody optimization and humanization. The company was founded by Robert Beecroft on November 22, 1983 and is headquartered in Victoria, Canada.

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Earnings data Q1 2025

Earnings data Q2 2025

Earnings data Q3 2025

IPA reports record revenue and seeks funding for future growth

IPA's Q2 '23 earnings call highlighted record revenue, strategic program consolidation, and advancements in R&D. While facing cash needs and the need to raise funds, the company remains optimistic about future partnerships and the potential for data management transactions.

Immunoprecise Antibodies reports strong revenue growth and strategic collaborations

Immunoprecise Antibodies Ltd (IPA) had a strong quarter with revenue growth and valuable research collaborations, positioning the company for future success despite operational challenges.
IPA's focus on innovation, disruptive AI-driven collaborations, and strategic changes to boost profits highlight a positive growth trajectory and commitment to addressing unmet medical needs.

Immunoprecise Antibodies reports record revenue, eyes strategic partnerships for growth

IPA's Q4 '23 earnings call reflects strong revenue growth, strategic collaborations, and a focus on operational efficiency, positioning the company for future success.
While facing financial challenges and the need for fundraising, IPA's technological strengths, partnerships, and market opportunities offer avenues for growth and innovation.
The company's performance highlights resilience in the biotech sector, with a clear roadmap for enhancing shareholder value and advancing R&D capabilities.

Immunoprecise Antibodies Ltd posts strong Q1 earnings, eyes U.S. investors

Immunoprecise Antibodies Ltd (IPA) reports robust Q1 2024 earnings, marked by significant revenue growth and improved financial metrics. The company showcases strengths in strategic leadership, cost management, and expansion initiatives, while facing challenges in managing net losses and financial transparency. IPA has opportunities to capitalize on its strengths and attract more investors through the SEC shelf offering.

Immunoprecise Antibodies Ltd reports record Q2 revenue growth

IPA's Q2 2024 earnings call showcased robust revenue growth, operational improvements, and strategic initiatives driving the company forward.
While facing industry challenges, IPA's focus on client trust, cost management, and innovation positions it well for future success.
The company's commitment to governance, shareholder engagement, and exploring new revenue streams highlights a proactive approach to growth.

Immunoprecise Antibodies Ltd (IPA) reports strong Q3 performance and strategic investments

Immunoprecise Antibodies Ltd (IPA) delivered a robust performance in Q3 2024, marked by revenue growth, profit margin improvements, and strategic investments in BioStrand. While facing a net loss, IPA maintains a healthy cash balance and focuses on R&D efficiency. The company's strengths in innovation and customer commitment position it well for future growth, with opportunities to leverage its momentum for market expansion.

Immunoprecise Antibodies (IPA) reports 19% revenue growth in 2024

Immunoprecise Antibodies Ltd (IPA) delivered strong financial performance in fiscal year 2024, with revenue growth, reduced operating expenses, and successful product launches. Strategic collaborations and industry recognition highlight IPA's competitive strengths. Addressing commercialization challenges and seizing growth opportunities will be key focus areas for future success.

Immunoprecise Antibodies reports revenue growth and strategic advancements in Q1

IPA's Q1 2025 performance reflects revenue growth driven by VHH antibody programs and strategic inventory management.
The company's strengths lie in its AI-driven platform, strong pipeline, and balanced revenue generation models.
Challenges include maintaining financial consistency, effective inventory management, and staying competitive in the evolving market.
Opportunities for IPA include sustained growth through fee-for-service work, revenue diversification via licensing, and leadership in biotechnology innovation.

Immunoprecise Antibodies reports revenue growth amidst financial challenges in Q2 2025

Immunoprecise Antibodies Ltd's Q2 2025 performance reflects revenue growth but also increased expenses and a net loss, highlighting financial challenges.
Strategic strengths include industry profile enhancement, strong research collaborations, and a commitment to innovation.
Challenges lie in cost management, operational realignment post-divestiture, and the need for revenue growth.
Opportunities exist in collaborations with semiconductor companies, market expansion through BioStrand, and strategic financial restructuring.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

ImmunoPrecise Antibodies Ltd. is a therapeutic antibody discovery company, which engages in the provision of human therapeutic antibody discovery and development services. The firm offers a selection of antibodies, enzymes, enzymes activity assays, arthritis animal products, proteins, deiminated proteins, and hybridoma licensing for research purposes. The company was founded by Robert Beecroft on November 22, 1983 and is headquartered in Victoria, Canada.

The stock price of Immunoprecise Antibodies Ltd (NASDAQ: IPA) is trading at over 10% pre-market. This is why it happened.

IPA Stock Price Increases Over 10% Pre-Market: Why It Happened

VICTORIA, British Columbia--(BUSINESS WIRE)---- $IPA #POLYTOPE--ImmunoPrecise Antibodies Ltd. (the "Company" or "IPA") (NASDAQ: IPA) (TSX Venture: IPA) announced preliminary, preclinical data in hamsters of IPA's proprietary TATX-03 PolyTope antibody cocktail program against SARS-CoV-2, the virus that causes COVID-19 disease. In a preclinical study using a SARS-CoV-2 hamster model, treatment with IPA's TATX-03 resulted in complete clearance of detectable replication-competent virus from the lungs and throat of SA

ImmunoPrecise Announces Data from Preclinical Study of TATX-03 PolyTope™ Monoclonal Antibody Cocktail Candidate Against COVID-19

VICTORIA, British Columbia--(BUSINESS WIRE)---- $IPA #POLYTOPE--IMMUNOPRECISE ANTIBODIES LTD. (the “Company” or “IPA”) (NASDAQ: IPA / TSX VENTURE: IPA) a leader in full-service, therapeutic antibody discovery and development, today announced that the over-allotment option (the “Option”) granted in connection with its previously announced bought deal offering of 1,616,293 common shares (the “Common Shares”) in the capital of the Company (the “Offering”), has been fully exercised. H.C. Wainwright & Co. has purc

IPA Announces Closing of Over-Allotment Option Associated with the Recently Completed Bought Deal Offering of Common Shares

VICTORIA, British Columbia--(BUSINESS WIRE)---- $IPA #POLYTOPE--IMMUNOPRECISE ANTIBODIES LTD. (the “Company” or “IPA”) (NASDAQ: IPA / TSX VENTURE: IPA) a leader in full-service, therapeutic antibody discovery and development, today announced that, it has closed its previously announced public offering (the “Offering”) of 1,616,293 common shares of the Company (the “Common Shares”), at a price to the public of $13.45 per Common Share, less underwriting discounts and commissions, for gross proceeds to the Company o

IPA Announces Closing of $21.7 Million Bought Deal Offering of Common Shares

VICTORIA, British Columbia--(BUSINESS WIRE)---- $IPA #POLYTOPE--IMMUNOPRECISE ANTIBODIES LTD. (the "Company" or "IPA") (NASDAQ: IPA) (TSX VENTURE: IPA) a leader in full-service, therapeutic antibody discovery and development, today announced that, due to demand, the underwriter has agreed to increase the size of the previously announced public offering and purchase on a firm commitment basis 1,616,293 common shares of the Company (the “Common Shares”), at a price to the public of $13.45 per Common Share, less und

IPA Increases Previously Announced Bought Deal Offering of Common Shares to $21.7 Million

VICTORIA, British Columbia--(BUSINESS WIRE)---- $IPA #POLYTOPE--IMMUNOPRECISE ANTIBODIES LTD. (the "Company" or "IPA") (NASDAQ: IPA) (TSX VENTURE: IPA) a leader in full-service, therapeutic antibody discovery and development, today announced that it has entered into an underwriting agreement with H.C. Wainwright & Co., LLC under which the underwriter has agreed to purchase on a firm commitment basis 743,495, common shares of the Company (the “Common Shares”), at a price to the public of $13.45 per Common Shar

IPA Announces $10.0 Million Bought Deal Offering of Common Shares

VICTORIA, British Columbia--(BUSINESS WIRE)---- $IPA #POLYTOPE--IMMUNOPRECISE ANTIBODIES LTD. (“IPA”) (Nasdaq: IPA) (TSXV: IPA) a leader in full-service, therapeutic antibody discovery, today announced that Dr. Jennifer Bath, ImmunoPrecise's Chief Executive Officer, will participate in a pre-recorded presentation through the H.C. Wainwright BioConnect 2021 Conference, and management will host one-on-one meetings with investors through the Stern IR Virtual Corporate Access Event, both taking place January 11-14, 2

ImmunoPrecise Antibodies to Participate in January Conferences

News for Immunoprecise Antibodies Ltd Stock (IPA)